Aytu BioPharma Posts $16.1 Million Quarter as EXXUA Scripts Jump 138%
Aytu BioPharma's fiscal fourth quarter brought $16.1 million of revenue, a 138% jump in EXXUA prescriptions and $0.5 million of positive adjusted EBITDA. The launch ramp now has to carry the company.
Aytu BioPharma Inc (AYTU) reported $16.1 million in fiscal fourth-quarter 2026 revenue, a 138% surge in EXXUA prescriptions and a swing to positive adjusted EBITDA of $0.5 million, with shares last closing at 2.23, up 4.94%.
Aytu BioPharma Inc (AYTU) closed the books on fiscal 2026 with the two numbers a small-cap specialty pharmaceutical company most needs at the same time: a launch that is accelerating and a profit line that has stopped bleeding. The company reported revenue of $16.1 million for the fiscal fourth quarter, said prescriptions for EXXUA rose 138%, and posted positive adjusted EBITDA of $0.5 million, according to management's remarks on the earnings call summarized by GuruFocus.
Shares last changed hands at 2.23, up 4.94% from the prior close of 2.13, with a session range of 2.14 to 2.33, as of the last trade on Tue, 22 Sep 2026 at 20:00 GMT. The market is closed. That move came against a flat broad tape: the S&P 500 proxy SPY finished at $773.38, down 0.02%, while the Nasdaq 100 proxy QQQ added 0.81% to $747.46 and the Dow 30 proxy DIA slipped 0.34% to $518.00.
Why the adjusted EBITDA line is the headline, not the revenue
Adjusted EBITDA — earnings before interest, taxes, depreciation and amortization, with certain one-time or non-cash items stripped out — is not a profit figure under standard accounting rules. It is, however, the metric small pharmaceutical companies and their lenders watch most closely, because it approximates whether the operating business is funding itself before financing costs.
For a company of Aytu's size, crossing from negative to positive on that line changes the conversation. A business burning cash every quarter is, sooner or later, a business that has to raise equity, and dilution at a share price near 2.23 is expensive. A business that generates even a small positive EBITDA has optionality: it can fund the next stage of a product launch out of the launch itself rather than out of the share count.
The caveat is scale. At $0.5 million on $16.1 million of revenue, the margin is thin enough that a single quarter of gross-to-net pressure, a rebate true-up or a step-up in promotional spend could push it back below zero. On an illustrative basis, $0.5 million against $16.1 million of revenue works out to roughly a 3% adjusted EBITDA margin — a threshold, not a cushion. The question for fiscal 2027 is not whether the company reached breakeven once, but whether it can stay there while spending to grow EXXUA.
What a 138% prescription jump does and does not tell you
EXXUA prescription growth of 138% is the number management wants investors anchored on, and it is a genuine signal — prescription volume is the cleanest leading indicator of a specialty launch, because it precedes recognized revenue by the length of the channel.
But percentage growth off a launch base is arithmetically generous. A new product moving from a small absolute prescription count to a slightly larger one produces triple-digit percentages that flatten quickly as the denominator grows. What matters over the coming quarters is the shape of the curve: whether new-to-brand prescriptions keep expanding the prescriber base, whether refill rates hold, and critically, what net price per script survives payer negotiation. Volume that arrives only through deep rebating converts poorly into revenue.
Investors will also be watching payer coverage breadth. A branded product in a category crowded with generics lives or dies on formulary position, and the cost of buying that position shows up in gross-to-net deductions rather than in the prescription count.
The legacy business still sets the floor
Aytu's revenue base has long rested on commercial products in ADHD and pediatric care — categories where branded assets face persistent generic and payer pressure. The strategic logic of the EXXUA launch is straightforward: build a growth asset that eventually outruns the erosion in the legacy portfolio.
Aytu's revenue base has long rested on commercial products in ADHD and pediatric care — categories where branded assets face persistent generic and payer pressure.
The mathematics of that transition are unforgiving. If the established portfolio declines while EXXUA climbs, total revenue can sit flat for several quarters even as the mix improves dramatically. That is often the most dangerous stretch for a small-cap: the story is getting better and the reported top line is not showing it. A quarter of $16.1 million is the reference point against which the next four will be judged. Annualized at that run rate — an illustrative calculation, not a company forecast — the business would be operating at roughly $64.4 million a year.
Mix also matters for profitability. A newly launched branded product typically carries a higher gross margin than mature commercial assets but a far heavier selling cost, because the field force and payer-access spending arrive before the volume. That is precisely why a positive EBITDA quarter during an accelerating launch is more notable than the same result during a harvest phase.
What to watch over the next four quarters
- Sequential EXXUA prescription trend. The percentage will compress as the base grows; the absolute weekly script count is the honest measure.
- Net revenue per prescription. Rising volume with falling net price is a treadmill, not a launch.
- Whether adjusted EBITDA stays positive. One quarter above the line is an event; four is a business model.
- Legacy portfolio erosion rate. The speed of the decline determines how fast EXXUA has to grow simply to hold the top line steady.
- Financing posture. Any capital raise, debt amendment or refinancing tells you more about the balance sheet than the EBITDA figure does.
How the market is pricing it
The 4.94% advance to 2.23 puts Aytu well ahead of the day's benchmarks, but a move of that size in a stock at this price level is a small absolute change and says little on its own. Low-priced small-cap pharmaceutical shares trade with wide percentage swings on modest volume, and a single session's direction should not be read as a verdict on the quarter.
The more useful frame is what the print removed. Before this report, the bear case rested on two pillars: that the launch was not converting to volume, and that the company could not reach operating breakeven without dilution. The quarter addressed both, at least for one reporting period. It did not address durability, and durability is the whole question. Specialty pharma launches routinely post an impressive first year of percentage growth, then stall when the early-adopter prescriber base is exhausted and payer economics tighten.
Fiscal 2027 guidance, prescription disclosure cadence and the cash balance at the next reporting date will decide whether this quarter marks an inflection or a high-water mark.
Key facts
- AYTU last close: 2.23, +4.94% (as of 22 Sep 2026, 20:00 GMT)
- Q4 FY2026 revenue: $16.1 million
- Adjusted EBITDA: Positive $0.5 million (swing from negative)
- EXXUA prescription growth: +138%
Frequently asked questions
What did Aytu BioPharma report for its fiscal fourth quarter of 2026?
Aytu BioPharma reported revenue of $16.1 million for the fiscal fourth quarter of 2026. On the same earnings call, management said prescriptions for EXXUA rose 138% and that the company swung to positive adjusted EBITDA of $0.5 million, reversing a prior negative result on that measure.
How did AYTU shares react?
AYTU last traded at 2.23, up 4.94% from a prior close of 2.13, with a session range of 2.14 to 2.33 as of the last trade on 22 September 2026 at 20:00 GMT. The market is closed. That gain outpaced the day's major benchmarks, which were roughly flat to modestly mixed.
What is adjusted EBITDA and why does it matter here?
Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, with certain one-time or non-cash items excluded. It is not a standard accounting profit measure, but for small pharmaceutical companies it approximates whether the operating business funds itself. Turning positive reduces the near-term pressure to raise equity at a low share price.
Is a 138% prescription increase as strong as it sounds?
It is a genuine positive signal, since prescription volume leads recognized revenue. But percentage growth from a small launch base is arithmetically generous and compresses as the denominator grows. The more durable measures are absolute weekly script counts, refill persistence, prescriber breadth and net revenue captured per prescription after payer rebates.
What is the main risk to Aytu's return to positive EBITDA?
Scale. At $0.5 million on $16.1 million of revenue the margin is very thin, so a rebate adjustment, gross-to-net pressure or a step-up in promotional spending behind the EXXUA launch could push the figure back below zero. Sustaining it across several consecutive quarters is a different achievement from reaching it once.
Why does the legacy ADHD and pediatric portfolio matter to the story?
Aytu's established commercial products face ongoing generic and payer pressure. If that portfolio declines while EXXUA grows, total revenue can stay flat for several quarters even as the product mix improves. The pace of legacy erosion determines how fast the new launch must ramp simply to keep the reported top line from shrinking.
